Activity Chair

Mark Sulkowski, MD
Mark Sulkowski, MD
Professor of Medicine, Medical Director of the Viral Hepatitis Center
Johns Hopkins School of Medicine
Baltimore, MD

Consulting Fee: AbbVie Inc., Cocrystar Pharma, Inc., Janssen, Merck & Co., Inc., Trek
Contracted Research: AbbVie Inc., Gilead Sciences, Inc., Janssen, Merck & Co., Inc.


Graham R. Foster, FRCP, PhD
Graham R. Foster, FRCP, PhD
Professor of Hepatology
Queen Mary, University of London
London, United Kingdom

Consulting Fee: AbbVie Inc., Alnylam UK Ltd., Bristol-Myers Squibb,
Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Merck & Co., Inc.,
Roche, Spring Bank Pharmaceuticals
Speakers Bureau: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc.,
Janssen, Merck & Co., Inc., Roche
Ownership Interest: GlaxoSmithKline

Ira M. Jacobson, MD
Chairman, Department of Medicine
Mount Sinai Beth Israel Medical Center
Vice Chair of Medicine
Mount Sinai Health Care System
Senior Faculty, Icahn School of Medicine at Mount Sinai
New York, NY

Consulting Fee: AbbVie Inc., Achillion Pharmaceuticals, Inc.,
Bristol-Myers Squibb, Intercept Pharmaceuticals, Inc., Gilead Sciences,
Inc., Janssen, Merck & Co., Inc., Trek
Speakers Bureau: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences,
Inc., Janssen
Contracted Research: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences,
Inc., Janssen, Merck & Co., Inc.

Stefan Zeuzem, MD
Professor of Medicine
Chief, Department of Medicine 
JW Goethe University Hospital 
Frankfurt, Germany

Consulting Fee: AbbVie Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Janssen,
Merck & Co., Inc.

Peer Reviewer

Joseph K. Lim, MD
Associate Professor of Medicine
Director, Yale Viral Hepatitis Program
Yale University School of Medicine
New Haven, CT

Consulting Fee: Bristol-Myers Squibb, Gilead
Contracted Research: Bristol-Myers Squibb, Gilead


Vindico Medical Education staff report the following relationship(s):

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accredited By

Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 1.0 Credits
Release Date: May 06, 2016
Expiration Date: May 06, 2017
Estimated Time to Complete Activity: 60 minutes
Registration Required: Yes
Fee for Activity: There is no fee for this educational activity

Activity Description

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. Rapid advancements in the field and interferon-free regimens approved for HCV, as well as several on the horizon, offer improved outcomes, shorter treatment durations, and unique adverse event profiles; therefore, clinicians must stay informed of the evolving data to counsel patients appropriately. Clinicians face challenges regarding how to make treatment choices among the numerous interferon-free regimens to improve treatment uptake and optimize outcomes in patients with HCV. This roundtable discussion among leading experts in HCV was recorded immediately following the 2016 EASL meeting in Barcelona, Spain, exploring some of the most recent findings and addressing the evidence-based clinical application of these data for HCV patients.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:
-Discuss the latest evidence for treatment duration in various patient populations with chronic hepatitis C virus (HCV) infection. 
-Discuss the treatment of HCV in challenging patients, such as those with rare or hard-to-treat HCV genotypes, advanced liver disease, chronic kidney disease, or who failed prior therapy. 
-Evaluate the latest groundbreaking data for emerging oral regimens for the treatment of chronic HCV infection.

Target Audience

The intended audience for the activity is gastroenterologists, hepatologists, gastroenterology/hepatology nurse practitioners and physician assistants, infectious disease physicians and other health care professionals involved in the treatment of patients with HCV.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the posttest and evaluation form. A score of at least 4 out of 5 is required on the posttest in order to receive a Certificate. There are no prerequisites, and there is no fee to participate in this activity or to receive CME credit. Credit is awarded upon successful completion of the posttest and evaluation form.



Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Accreditation Statement

This continuing medical education activity is provided by Vindico Medical Education.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). The AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Nurse practitioners can also apply for credit through their state boards.

The American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

Instructions for Receiving Credit

Follow these steps to earn CME credit:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie and Merck & Co., Inc.

Disclaimer Statement/ Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

The opinions expressed herein are those of the authors and do not necessarily represent the views of Vindico Medical Education. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact Vindico Medical Education at


Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2016 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Hardware / Software Requirements

OpenCME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.